PDGFRα is a tyrosine kinase receptor for PDGFA, PDGFB and PDGFC, and plays essential roles during development, cell fate determination, migration and cell differentiation (Hoch and Soriano 2003) . PDGF signaling regulates the differentiation of mesenchymal cell types and increased activation of PDGFRα leads to connective tissue hyperplasia -also called fibrosis- (Olson and Soriano 2009) , a hallmark of several skeletal muscle disorders. PDGFRα is a marker of fibroadipogenic progenitors (FAPs) and is up regulated in models of acute and chronic skeletal muscle damage (Contreras et al. 2016 , Joe et al., 2010 , Uezumi et al., 2010 , Uezumi et al., 2011 . Thus, PDGFRα signaling regulation needs to be fine-tuned in order to maintain tissue homeostasis and regeneration. Mueller et al. (2016) , using the PDGFRα H2B-eGFP knock-in mice (Hamilton et al., 2003) and direct RNA sequencing, found a new transcriptional variant of Pdgfra BIn-PDGFRα^, which is polyadenylated in intron 16 in FAPs (Mueller et al., 2016) . This In-PDGFRα variant produces a truncated protein that lacks its kinase domain 2 (KD2) and acts as a decoy for PDGFRα signaling, hence limiting FAPs over-activation during healthy muscle regeneration. Thus, in vivo enhancing of the In-PDGFRα variant using vivo morpholino nucleotides (VMOs) attenuates muscle fibrosis, while down regulation of In-PDGFRα leads to increase fibrosis in the injured muscle. Interestingly, gene expression analysis of FAPs isolated from injured muscles with decreased In-PDGFRα (i.e. fibrotic milieu) led to the discovery of key molecular fibrotic networks, such as Tgf-β1 and Ctgf. Altogether, these results indicate that modulating PDGF signaling in FAPs in vitro and in vivo affect FAPs activity and muscle fibrosis.
This work shows that changes in the polyadenylation pattern of Pdgfra regulate the biology of interstitial progenitor cells during muscle regeneration. Due to the roles of TGF-β1 and CTGF in muscular dystrophies and fibrosis (Ceco and McNally 2013, Morales et al. 2013) we hypothesize that PDGFRα could act as a modulator of fibrogenesis and connective tissue remodeling in conjunction with these profibrotic proteins during the progression of the disease. Remarkably, treatment with the tyrosine kinase inhibitor Nilotinib reduces PDGFRα signaling, FAPs activity and fibrosis during muscle chronic damage (Lemos et al. 2015) . Thus, there is a necessity in understanding the behavior of FAPs and the role of PDGFRα under fibrotic conditions for the development of new therapies for several muscle pathologies.
